Thymopentin increases the survival of mice after allogeneic blood transfusion, bacterial gavage, and burn injury
Braga, M.; Di Francesco, A.; Gianotti, L.; Vignali, A.; Costantini, E.; Socci, C.; Fortis, C.; Paganelli, G.; Di Carlo, V.
European Journal of Surgery 160(6-7): 345-350
1994
ISSN/ISBN: 1102-4151 PMID: 7948352 Document Number: 433774
Objective: To investigate the effect of blood transfusion on mortality and the incidence of bacterial translocation in mice subjected to thermal burn or bacterial gavage, or both, and to assess the influence of thymopentin on mortality. Design: Randomly controlled experiments. Setting: University departments of surgery, immunology and nuclear medicine. Material. 235 Balb/c (H-2-d) and C3H/HeJ (H-2-k) mice Interventions: 8 groups of 20 mice each received: saline infusion (controls), blood transfusion (BT) alone, 20% bum alone, gavage with 1 times 10-10 Escherichia coli alone, BT and gavage, BT and bum, bum and gavage, or BT, burn, and gavage. A further 3 groups of 10 mice were all gavaged with 111In-biotin labelled E. coli and randomised to additional BT and burn, BT alone, or burn alone. 98 mice that had had BT, burn, and gavage, were then randomised to receive thymopentin 0, 0. 1, 1, or 5 mg/kg/day for 15 days. The impact of the pretreatment with thymopentin on PGE-2 Concentration was also evaluated in a separate group of 45 mice that received BT, bum, and gavage; or bum and gavage. Main outcome measures: Survival, degree of translocation. Results: The highest mortality (75%) was in the BT, bum, and gavage group. BT alone significantly reduced survival in burned mice, whereas BT alone or associated with gavage had no effect. Thermal injury had the most influence on bacterial translocation, whereas BT did not increase it. Thymopentin significantly improved survival, particularly in the higher doses. The pretreatment with thymopentin significantly reduced PGE-2 concentration after BT, burn and gavage. Conclusion: Burn injury significantly increased mortality in the presence of immune deficiency caused by BT. Thymopentin reduced mortality, possibly by immunomodulation.